Endoscopic Application of Hemostatic Drug Powder in Lower Gastrointestinal Bleeding: A Pilot Study

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorNational Cheng-Kung University Hospital

About this trial

This clinical trial will enroll patients at National Cheng Kung University Hospital. All patients who are hospitalized for lower gastrointestinal bleeding and undergo colonoscopy will be invited to participate. This study uses random allocation, with one Intervention group and one Standard group. Both groups will receive standard endoscopic hemostasis. Afterward, patients in the Intervention group will receive local administration of 1.5 g of tranexamic acid and 3 g of sucralfate. Following the endoscopic procedure, patients will be directly observed for 5 minutes to confirm successful hemostasis. All patients will be followed for 28 days to assess the occurrence of post-procedural rebleeding.

Eligibility criteria

Qualifiers

patients suspect lower gastrointestinal bleeding

Disqualifiers

absence of indication for endoscopic hemostasis

known allergy to sucralfate, TXA

presence of a hollow organ perforation

Trial design

Treatments tested in this trial

  • Tranexamic acid and sucralfate powder spray
  • Standard endsocopic hemostasis

Treatment groups

60 Participants
are divided into 2 treatment groups

Locations

This trial has no locations